Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immun...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will be presented during poster sessions on Monday, March 6, at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place March 3–6, 2017, in Atlanta, Georgia. The presentations will report data from the Phase 2 ARC001 study (Abstract 803) and from the screening population of the PALISADE Phase 3 study (Abstracts L20 and 807). Presentation details are as follows:

Abstract 803: Jones S, et al., At-home dosing adherence during characterized oral desensitization immunotherapy (CODIT) for peanut allergy; Poster Session #4210 on Allergen Extracts and Other Forms of Immunotherapy, 9:45 AM – 10:45 AM Eastern Time, Monday, March 6, 2017, in Building B, Level 1, Exhibit Hall B2. The abstract may be viewed online at http://www.jacionline.org/article/S0091-6749(16)32342-9/pdf.

Abstract L20: Vickery BP, et al., Outcome of 583 entry double-blind placebo-controlled peanut challenges during screening for the PALISADE Phase 3 oral immunotherapy trial; Late Breaking Poster Session #4213, 9:45 AM - 10:45 AM Eastern Time, Monday, March 6, 2017, in Building B, Level 1, Exhibit Hall B2. The abstract may be viewed online at http://www.jacionline.org/article/S0091-6749(16)32432-0/pdf.

Abstract 807: Rust B, et al., Dual assessment of peanut-specific effector and regulatory T cells in patients undergoing oral immunotherapy; Poster Session #4210 on Allergen Extracts and Other Forms of Immunotherapy, 9:45 AM – 10:45 AM Eastern Time, Monday, March 6, 2017, in Building B, Level 1, Exhibit Hall B2. The abstract may be viewed online at http://www.jacionline.org/article/S0091-6749(16)32346-6/pdf.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts. For more information, please see www.aimmune.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170227005327/en/

Aimmune Therapeutics, IncInvestorsLaura Hansen, Ph.D., [e-mail] Yao, [e-mail]